Navigation Links
Building a better mouse model to understand pancreatic cancer

(SALT LAKE CITY)Cancer of the pancreas is usually not detected until it's too late to cure. But precursor lesions that form in the pancreas and its ducts can signal the disease before it strikes, and when caught early enough, they can be prevented from progressing to become cancer.

In a new study, researchers led by a molecular biologist at the University of California, San Francisco (UCSF), report two breakthroughs in understanding those lesions and their role in pancreatic cancer: the development of the first mouse model that simulates a precursor lesion called intraductal papillary mucinous neoplasia (IPMN), and the identification of an enzyme, Brg1, that appears to help cause the formation of IPMN lesions while also suppressing another precursor lesion.

A University of Utah co-author on the study says the research proves that epigenetics changes in genetic activity caused by forces other than modifications in the DNA sequence, such as when genes are turned on or off play a role in pancreatic ductal adenocarcinoma (PDA), the most common type of cancer of the pancreas. "These findings may provide an avenue for intervention in PDA, if we can understand the epigenetics," says Matthew A. Firpo, Ph.D., research associate professor of surgery.

Mathias Hebrok, Ph.D., of UCSF School of Medicine, led the study published on Sunday, Feb. 23, 2014, in Nature Cell Biology. Sean J. Mulvihill, M.D., University of Utah professor of surgery, associate vice president for clinical affairs and CEO of the University of Utah Medical Group, is also a co-author on the paper. He and Firpo have banked human samples of IPMN for many years and shared some with Hebrok for his research.

"This study not only represents a longstanding collaboration between the University of Utah and UCSF but also is a reflection of the transition in research from single investigators working on their own to highly collaborative studies with experts in many fields from different institutions," says Mulvihill, who is also a pancreatic cancer surgeon and an investigator with the University of Utah's Huntsman Cancer Institute.

With a five-year survival rate of just 4.4 percent, cancer of the pancreas is the fourth leading cause of cancer deaths. In 82 percent of cases, the disease is found when it's too late to remove the tumor. Tumors that are smaller than 2 centimeters and haven't metastasized are considered the best cases for surgery. When tumors are operable, the five-year survival rate approaches 40 percent, according to Firpo.

IPMN is one of three classes of pancreatic cancer precursor lesions. Pancreatic Intraepithelial Neoplasia (PanIN) and mucinous cystic neoplasm (MCN) also are lesions that precede pancreatic cancer. PanINs are the lesions most commonly thought to lead to PDA.

Brg1 is an enzyme that regulates gene expression by altering DNA structure in the nucleus of a cell, a process known as chromatin remodeling. Hebrok found that when the Brg1 gene is knocked out in mice that are predisposed to PanIN development and subsequent PDA, lesions form that are similar to human IPMN. He confirmed that through the human IPMN samples from Mulvihill and Firpo.

But in addition to Brg1's role in forming IPMN lesions, Hebrok discovered that when the gene is knocked out in mice that have an activated gene called KRAS, whose role is to help regulate cell division, PanIN lesions occur less frequently. This indicates that Brg1 protects against PanIns but also helps cause IPMN lesions.

"As someone who researches pancreatic cancer, I think this discovery is significant because it defines mechanisms that lead to this cancer in ways that we didn't know about before," says Firpo, who's also a member of the Pancreas Cancer Research Program and Experimental Therapeutics Program at the University of Utah's Huntsman Cancer Institute. "It illuminates an area that were just guessing at before."

It's also significant because people with IPMN, which has been more frequently diagnosed in recent years, have a much better prognosis for survival than those with PanINs. The symptoms of IPMN usually become noticeable before cancer develops, meaning the lesions can be treated before a cancerous tumor forms. PanINs, however, typically don't show symptoms before an inoperable tumor has formed.

That's why it is so important to find the disease as early as possible, according to Mulvihill. "Better understanding of the beginnings of pancreatic cancer gives us much more hope for both prevention and cure."


Contact: Phil Sahm
University of Utah Health Sciences

Related medicine news :

1. Body Building, Diet Supplements Linked to Liver Damage: Study
2. Germ Culprits in Moldy, Water-Damaged Buildings Identified
3. Building a better Rift Valley fever vaccine
4. Heuer M.D. Research Announces CardiaShred™ - First Medical Doctor Formulated, Heart Healthy Weight Loss, Energy and Lean Muscle Building Supplement
5. Kessler Foundation presents Brain Injury: From Research to Rebuilding Lives on Sept. 27-28
6. Rebuilding a whole heart for children born with only half of 1
7. UC research explores relationship-building program for male same-sex couples
8. Dental Marketing has been Featured in The LA Daily News for their Specialized Practice Building Solutions in the Dental Industry
9. Steering stem cells to become 2 different building blocks for new blood vessels
10. Rebuilding blood vessels through gene therapy
11. Visual Impact Muscle Building: Review Examining Rusty Moore's Training Program Released By
Post Your Comments:
(Date:11/27/2015)... ... , ... A simply groundbreaking television series, "Voices in America", which is hosted ... array of issues that are presently affecting Americans. Dedicated to providing the world with ... changing the subjects consumers focus on, one episode at a time. , In ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... successful and prominent nonprofit healthcare organizations in the country. They have overseen financial ... organizations, and helped advance the healthcare industry as a whole through their advocacy ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point ... come together on Thanksgiving Day to share the things that they are most ... Serenity Point YouTube channel, patients displayed what they wrote on index cards, describing ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... to discuss bioavailability and the need to integrate dose form selection in early ... with OBN, the membership organization supporting and bringing together the UK’s emerging life ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel ... self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes with ... work with any font, giving users limitless opportunities to stylize and create designs ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 26, 2015 Research and Markets ( ) ... Pacemaker Market Outlook to 2019 - Rise in Cardiac Disorders ... report to their offering. Boston ... Boston scientific and others. --> ... Biotronik, Boston scientific and others. ...
(Date:11/26/2015)... 26, 2015 ... "2016 Future Horizons and Growth Strategies ... Market: Supplier Shares, Country Segment Forecasts, Competitive ... offering. --> ) has ... Future Horizons and Growth Strategies in the ...
(Date:11/26/2015)... 2015 ) has ... of High Viscosity Drugs" report to their ... the addition of the "Self Administration of ... --> Research and Markets ( ... "Self Administration of High Viscosity Drugs" report ...
Breaking Medicine Technology: